LIVIVO - Search results -

Search results

Result 1 - 10 of total 20

Search options

Article ; Online: AQDnet: Deep Neural Network for Protein-Ligand Docking Simulation.

Shiota, Koji / Suma, Akira / Ogawa, Hiroyuki / Yamaguchi, Takuya / Iida, Akio / Hata, Takahiro / Matsushita, Mutsuyoshi / Akutsu, Tatsuya / Tateno, Masaru

ACS omega

2023 Volume 8, Issue 26, Page(s) 23925–23935

Abstract: We have developed an innovative system, AI QM Docking Net (AQDnet), which utilizes the three-dimensional structure of protein-ligand complexes to predict binding affinity. This system is novel in two respects: first, it significantly expands the training ...

Abstract	We have developed an innovative system, AI QM Docking Net (AQDnet), which utilizes the three-dimensional structure of protein-ligand complexes to predict binding affinity. This system is novel in two respects: first, it significantly expands the training dataset by generating thousands of diverse ligand configurations for each protein-ligand complex and subsequently determining the binding energy of each configuration through quantum computation. Second, we have devised a method that incorporates the atom-centered symmetry function (ACSF), highly effective in describing molecular energies, for the prediction of protein-ligand interactions. These advancements have enabled us to effectively train a neural network to learn the protein-ligand quantum energy landscape (P-L QEL). Consequently, we have achieved a 92.6% top 1 success rate in the CASF-2016 docking power, placing first among all models assessed in the CASF-2016, thus demonstrating the exceptional docking performance of our model.
Language	English
Publishing date	2023-06-16
Publishing country	United States
Document type	Journal Article
ISSN	2470-1343
ISSN (online)	2470-1343
DOI	10.1021/acsomega.3c02411
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Therapeutic Effect of Colony Stimulating Factor 1 Receptor Kinase Inhibitor, JTE-952, on Methotrexate-Refractory Pathology in a Rat Model of Rheumatoid Arthritis.

Uesato, Naofumi / Kitagawa, Yoshihiro / Matsuo, Yushi / Miyagawa, Naoki / Inagaki, Koji / Kakefuda, Reina / Yamaguchi, Takayuki / Hata, Takahiro / Ikegashira, Kazutaka / Matsushita, Mutsuyoshi

Biological & pharmaceutical bulletin

2023 Volume 46, Issue 9, Page(s) 1223–1230

Abstract: Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation and the destruction of bone and cartilage in affected joints. One of the unmet medical needs in the treatment of RA is to effectively prevent the structural destruction of ... ...

Abstract	Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation and the destruction of bone and cartilage in affected joints. One of the unmet medical needs in the treatment of RA is to effectively prevent the structural destruction of joints, especially bone, which progresses because of resistance to conventional drugs that mainly have anti-inflammatory effects, and directly leads to a decline in the QOL of patients. We previously developed a novel and orally available type II kinase inhibitor of colony-stimulating factor-1 receptor (CSF1R), JTE-952. CSF1R is specifically expressed by monocytic-lineage cells, including bone-resorbing osteoclasts, and is important for promoting the differentiation and proliferation of osteoclasts. In the present study, we investigated the therapeutic effect of JTE-952 on methotrexate (MTX)-refractory joint destruction in a clinically established adjuvant-induced arthritis rat model. JTE-952 did not suppress paw swelling under inflammatory conditions, but it inhibited the destruction of joint structural components including bone and cartilage in the inflamed joints. In addition, decreased range of joint motion and mechanical hyperalgesia after disease onset were suppressed by JTE-952. These results suggest that JTE-952 is expected to prevent the progression of the structural destruction of joints and its associated effects on joint motion and pain by inhibiting CSF1/CSF1R signaling in RA pathology, which is resistant to conventional disease-modifying anti-rheumatic drugs such as MTX.
MeSH term(s)	Animals ; Rats ; Methotrexate/pharmacology ; Methotrexate/therapeutic use ; Macrophage Colony-Stimulating Factor ; Quality of Life ; Antineoplastic Agents ; Arthritis, Rheumatoid/drug therapy ; Receptor Protein-Tyrosine Kinases
Chemical Substances	Methotrexate (YL5FZ2Y5U1) ; JTE-952 ; Macrophage Colony-Stimulating Factor (81627-83-0) ; Antineoplastic Agents ; Receptor Protein-Tyrosine Kinases (EC 2.7.10.1)
Language	English
Publishing date	2023-09-03
Publishing country	Japan
Document type	Journal Article
ZDB-ID	1150271-x
ISSN	1347-5215 ; 0918-6158
ISSN (online)	1347-5215
ISSN	0918-6158
DOI	10.1248/bpb.b23-00148
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1474: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Nonmechanical axial scanning laser Doppler velocimeter with directional discrimination.

Maru, Koichi / Hata, Takahiro

Applied optics

2012 Volume 51, Issue 20, Page(s) 4783–4787

Abstract: An axial scanning laser Doppler velocimeter (LDV) with directional discrimination not requiring any moving mechanism in its probe is proposed. The proposed LDV utilizes frequency shift induced by acousto-optic modulators (AOMs) for discriminating the ... ...

Abstract	An axial scanning laser Doppler velocimeter (LDV) with directional discrimination not requiring any moving mechanism in its probe is proposed. The proposed LDV utilizes frequency shift induced by acousto-optic modulators (AOMs) for discriminating the direction of velocity. The measurement position is axially scanned by changing the wavelength of the light input to the probe. The experimental result reveals that both the axial scan and the directional discrimination can be realized by using the proposed method without any moving element in the probe.
Language	English
Publishing date	2012-07-10
Publishing country	United States
Document type	Journal Article
ISSN	1539-4522
ISSN (online)	1539-4522
DOI	10.1364/AO.51.004783
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Nonmechanical scanning laser Doppler velocimeter for cross-sectional two-dimensional velocity measurement.

Maru, Koichi / Hata, Takahiro

Applied optics

2012 Volume 51, Issue 34, Page(s) 8177–8183

Abstract: We propose a two-dimensional scanning laser Doppler velocimeter (LDV) that does not require any moving mechanisms in its probe. In the proposed LDV, the measurement position can be scanned in two dimensions on a cross-sectional plane perpendicular to the ...

Abstract	We propose a two-dimensional scanning laser Doppler velocimeter (LDV) that does not require any moving mechanisms in its probe. In the proposed LDV, the measurement position can be scanned in two dimensions on a cross-sectional plane perpendicular to the direction of flow. The combination of the change in wavelength and change in port of the fiber array input to the probe is utilized for the scan. The experimental results using a sensor probe setup indicate that the measurement position can be scanned in two dimensions using the proposed method. The scanning range was estimated to be 39.7 mm in the axial direction over the wavelength range of 1536-1554 nm and 26.1 mm in the transverse direction for the use of 22 ports of the fiber array.
Language	English
Publishing date	2012-12-01
Publishing country	United States
Document type	Journal Article
ISSN	1539-4522
ISSN (online)	1539-4522
DOI	10.1364/AO.51.008177
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Pharmacological Properties of JTE-952, an Orally Available and Selective Colony Stimulating Factor 1 Receptor Kinase Inhibitor.

Uesato, Naofumi / Miyagawa, Naoki / Inagaki, Koji / Kakefuda, Reina / Kitagawa, Yoshihiro / Matsuo, Yushi / Yamaguchi, Takayuki / Hata, Takahiro / Ikegashira, Kazutaka / Matsushita, Mutsuyoshi

Biological & pharmaceutical bulletin

2020 Volume 43, Issue 2, Page(s) 325–333

Abstract: Colony stimulating factor 1 (CSF1) receptor (CSF1R) is a receptor protein-tyrosine kinase specifically expressed in monocyte-lineage cells, such as monocytes and macrophages. In this study, we characterized the pharmacological properties of an azetidine ... ...

Abstract	Colony stimulating factor 1 (CSF1) receptor (CSF1R) is a receptor protein-tyrosine kinase specifically expressed in monocyte-lineage cells, such as monocytes and macrophages. In this study, we characterized the pharmacological properties of an azetidine compound, JTE-952 ((2S)-3-{[2-({3-[4-(4-cyclopropylbenzyloxy)-3-methoxyphenyl]azetidine-1-yl}carbonyl)pyridin-4-yl]methoxy}propane-1,2-diol), which is a novel CSF1R tyrosine kinase inhibitor. JTE-952 potently inhibited human CSF1R kinase activity, with a half maximal inhibitory concentration of 11.1 nmol/L, and inhibited the phosphorylation of CSF1R in human macrophages and the CSF1-induced proliferation of human macrophages. It also inhibited human tropomyosin-related kinase A activity, but only at concentrations 200-fold higher than that required to inhibit the activity of CSF1R in inducing the proliferation of human macrophages. JTE-952 displayed no marked inhibitory activity against other kinases. JTE-952 potently inhibited lipopolysaccharide-induced proinflammatory cytokine production by human macrophages and in whole blood. JTE-952 (≥3 mg/kg given orally) also significantly attenuated the CSF1-induced priming of lipopolysaccharide-induced tumor necrosis factor-alpha production in mice and arthritis severity in a mouse model of collagen-induced arthritis. Taken together, these results indicate that JTE-952 is an orally available compound with potent and specific inhibitory activity against CSF1R, both in vitro and in vivo. JTE-952 is a potentially clinically useful agent for various human inflammatory diseases, including rheumatoid arthritis.
MeSH term(s)	Animals ; Arthritis, Experimental/drug therapy ; Azetidines/pharmacokinetics ; Azetidines/pharmacology ; Cells, Cultured ; Cytokines/blood ; Cytokines/metabolism ; Humans ; Male ; Mice ; Mice, Inbred DBA ; Protein Kinase Inhibitors/pharmacology ; Rats, Inbred Lew ; Receptor, trkA/metabolism ; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor/metabolism
Chemical Substances	Azetidines ; CSF1R protein, human ; Cytokines ; JTE-952 ; NTRK1 protein, human ; Protein Kinase Inhibitors ; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor ; Receptor, trkA (EC 2.7.10.1)
Language	English
Publishing date	2020-01-27
Publishing country	Japan
Document type	Journal Article
ZDB-ID	1150271-x
ISSN	1347-5215 ; 0918-6158
ISSN (online)	1347-5215
ISSN	0918-6158
DOI	10.1248/bpb.b19-00694
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1474: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: JTE-952 Suppresses Bone Destruction in Collagen-Induced Arthritis in Mice by Inhibiting Colony Stimulating Factor 1 Receptor.

Uesato, Naofumi / Inagaki, Koji / Miyagawa, Naoki / Kitagawa, Yoshihiro / Kakefuda, Reina / Matsuo, Yushi / Yamaguchi, Takayuki / Hata, Takahiro / Ikegashira, Kazutaka / Matsushita, Mutsuyoshi

Biological & pharmaceutical bulletin

2020 Volume 43, Issue 12, Page(s) 1884–1892

Abstract: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial inflammation and structural destruction of the joints. Bone damage occurs in an early stage after onset and osteoclast activation plays a substantial role in its ... ...

Abstract	Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial inflammation and structural destruction of the joints. Bone damage occurs in an early stage after onset and osteoclast activation plays a substantial role in its progression. Colony stimulating factor 1 receptor (CSF1R) is a receptor protein tyrosine kinase specifically expressed in monocytic-lineage cells such as macrophages and osteoclasts. Here, we investigated the effect of JTE-952, a novel CSF1R tyrosine kinase inhibitor, on osteoclast formation in vitro and on bone destruction in a mouse model of collagen-induced arthritis. JTE-952 completely inhibited osteoclast differentiation from human monocytes, with an IC
MeSH term(s)	Animals ; Arthritis, Experimental/drug therapy ; Arthritis, Experimental/metabolism ; Arthritis, Experimental/pathology ; Azetidines/pharmacology ; Azetidines/therapeutic use ; Bone Density/drug effects ; Bone Density/physiology ; Dose-Response Relationship, Drug ; Humans ; Male ; Mice ; Mice, Inbred DBA ; Osteoclasts/drug effects ; Osteoclasts/metabolism ; Osteoclasts/pathology ; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor/antagonists & inhibitors ; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor/metabolism ; Synovial Membrane/drug effects ; Synovial Membrane/metabolism ; Synovial Membrane/pathology
Chemical Substances	Azetidines ; Csf1r protein, mouse ; JTE-952 ; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor
Language	English
Publishing date	2020-10-01
Publishing country	Japan
Document type	Journal Article
ZDB-ID	1150271-x
ISSN	1347-5215 ; 0918-6158
ISSN (online)	1347-5215
ISSN	0918-6158
DOI	10.1248/bpb.b20-00517
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1474: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: JTE-852, a novel spleen tyrosine kinase inhibitor, blocks antigen-induced allergic reactions in rats.

Kato, Toshinobu / Ohta, Takeshi / Iwasaki, Hidenori / Kobayashi, Hatsue / Matsuo, Akira / Hata, Takahiro / Matsushita, Mutsuyoshi

The Journal of veterinary medical science

2018 Volume 80, Issue 3, Page(s) 465–472

Abstract: Conventional clinical treatments for allergy management remain suboptimal; new, orally available medications that improve a wide range of allergic signs have been desired. We previously demonstrated that JTE-852, a novel spleen tyrosine kinase inhibitor, ...

Abstract	Conventional clinical treatments for allergy management remain suboptimal; new, orally available medications that improve a wide range of allergic signs have been desired. We previously demonstrated that JTE-852, a novel spleen tyrosine kinase inhibitor, potently and simultaneously suppresses secretion of granule contents, arachidonate metabolites, and cytokines from mast cells stimulated by immunoglobulin E-crosslinking. In the present study, we investigated the effects of JTE-852 in four rat models (sneezing, rhinorrhea, airway constriction, and airway inflammation) as representatives of allergy models. Rats were sensitized and challenged with antigen. Allergic reactions developed after challenge were detected. JTE-852 and current anti-allergic drugs (ketotifen, pranlukast, and prednisolone) were administered orally before challenge. JTE-852 showed significant blocking effects on antigen-induced allergic reactions in all models, indicating that JTE-852 in oral dosage form would improve a wide range of allergic signs. The current anti-allergic drugs, on the other hand, failed to display significant suppression in several models. Because JTE-852 suppresses the secretion of all three groups of allergic mediators from mast cells, it would be capable of targeting signs that current drugs cannot sufficiently relieve. We anticipate JTE-852 to be a promising new anti-allergic drug that is potentially more effective than conventional drugs.
MeSH term(s)	Airway Obstruction/drug therapy ; Aminopyridines/pharmacology ; Animals ; Antigens/immunology ; Cytokines/metabolism ; Disease Models, Animal ; Hypersensitivity/drug therapy ; Hypersensitivity/immunology ; Male ; Mast Cells/metabolism ; Nasal Mucosa/drug effects ; Nasal Mucosa/secretion ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Rats ; Rats, Inbred BN ; Respiratory Hypersensitivity/drug therapy ; Sneezing/drug effects ; Spleen/enzymology ; Thiazoles/pharmacology
Chemical Substances	Aminopyridines ; Antigens ; Cytokines ; JTE-852 ; Thiazoles ; Protein-Tyrosine Kinases (EC 2.7.10.1)
Language	English
Publishing date	2018-01-26
Publishing country	Japan
Document type	Journal Article
ZDB-ID	1071753-5
ISSN	1347-7439 ; 0916-7250
ISSN (online)	1347-7439
ISSN	0916-7250
DOI	10.1292/jvms.17-0659
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 579: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: JTP-117968, a novel selective glucocorticoid receptor modulator, exhibits significant anti-inflammatory effect while maintaining bone mineral density in mice.

Kurimoto, Takafumi / Tamai, Isao / Nakagawa, Takashi / Miyai, Atsuko / Yamamoto, Yasuo / Kosugi, Yoshinori / Deai, Katsuya / Hata, Takahiro / Ohta, Takeshi / Matsushita, Mutsuyoshi / Yamada, Takahisa

European journal of pharmacology

2021 Volume 895, Page(s) 173880

Abstract: Classic glucocorticoids have been prescribed for various inflammatory diseases, such as rheumatoid arthritis, due to their outstanding anti-inflammatory effects. However, glucocorticoids cause numerous unwanted side effects, including osteoporosis and ... ...

Abstract	Classic glucocorticoids have been prescribed for various inflammatory diseases, such as rheumatoid arthritis, due to their outstanding anti-inflammatory effects. However, glucocorticoids cause numerous unwanted side effects, including osteoporosis and diabetes. Hence, selective glucocorticoid receptor modulators (SGRMs), which retain anti-inflammatory effects with minimized side effects, are among the most anticipated drugs in the clinical field. The assumption is that there are two major mechanisms of action via glucocorticoid receptors, transrepression (TR) and transactivation (TA). In general, anti-inflammatory effects of glucocorticoids are largely due to TR, while the side effects associated with glucocorticoids are mostly mediated through TA. We previously reported that JTP-117968, a novel SGRM, maintained partial TR activity while remarkably reducing the TA activity. In this study, we investigated the anti-inflammatory effect of JTP-117968 on a lipopolysaccharide (LPS) challenge model and collagen-induced arthritis (CIA) model in mice. Meanwhile, we tested the effect of JTP-117968 on the bone mineral density (BMD) in mouse femur to evaluate the side effect. Based on the evaluation, JTP-117968 reduced the plasma levels of tumor necrosis factor α induced by LPS challenge in mice significantly. Remarkably, CIA development was suppressed by JTP-117968 comparably with prednisolone and PF-802, an active form of fosdagrocorat that has been developed clinically as an orally available SGRM. Strikingly, the side effect of JTP-117968 on mouse femoral BMD was much lower than those of PF-802 and prednisolone. Therefore, JTP-117968 has attractive potential as a new therapeutic option against inflammatory diseases with minimized side effects compared to classic glucocorticoids.
MeSH term(s)	Aminopyridines/pharmacology ; Aminopyridines/toxicity ; Animals ; Anti-Inflammatory Agents/pharmacology ; Anti-Inflammatory Agents/toxicity ; Arthritis, Experimental/metabolism ; Arthritis, Experimental/pathology ; Arthritis, Experimental/prevention & control ; Bone Density/drug effects ; Female ; Glucocorticoids/pharmacology ; Glucocorticoids/toxicity ; Humans ; Inflammation Mediators/blood ; Intercellular Signaling Peptides and Proteins/genetics ; Intercellular Signaling Peptides and Proteins/metabolism ; Joints/drug effects ; Joints/metabolism ; Joints/pathology ; Male ; Mice, Inbred BALB C ; Mice, Inbred DBA ; Osteoblasts/drug effects ; Osteoblasts/metabolism ; Phenanthrolines/pharmacology ; Phenanthrolines/toxicity ; Receptors, Glucocorticoid/agonists ; Receptors, Glucocorticoid/metabolism ; Tumor Necrosis Factor-alpha/blood ; Mice
Chemical Substances	Aminopyridines ; Anti-Inflammatory Agents ; DKK1 protein, human ; Glucocorticoids ; Inflammation Mediators ; Intercellular Signaling Peptides and Proteins ; JTP-117968 ; Phenanthrolines ; Receptors, Glucocorticoid ; Tnf protein, mouse ; Tumor Necrosis Factor-alpha
Language	English
Publishing date	2021-01-18
Publishing country	Netherlands
Document type	Comparative Study ; Journal Article
ZDB-ID	80121-5
ISSN	1879-0712 ; 0014-2999
ISSN (online)	1879-0712
ISSN	0014-2999
DOI	10.1016/j.ejphar.2021.173880
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 522: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: JTE-852, a novel spleen tyrosine kinase inhibitor, blocks immunoglobulin G-mediated cellular responses and autoimmune reactions in vivo.

Kato, Toshinobu / Ohta, Takeshi / Iwasaki, Hidenori / Kobayashi, Hatsue / Matsuo, Akira / Hata, Takahiro / Matsushita, Mutsuyoshi

Life sciences

2017 Volume 191, Page(s) 166–174

Abstract: Aims: Immune and inflammatory responses mediated by immunoglobulin (Ig) G are largely responsible for the pathogenesis of autoimmune diseases. Spleen tyrosine kinase (Syk) plays a pivotal role in the IgG-mediated responses; therefore, Syk has emerged as ...

Abstract	Aims: Immune and inflammatory responses mediated by immunoglobulin (Ig) G are largely responsible for the pathogenesis of autoimmune diseases. Spleen tyrosine kinase (Syk) plays a pivotal role in the IgG-mediated responses; therefore, Syk has emerged as a new therapeutic target for the treatment of autoimmune diseases. In this study, we investigated the inhibitory actions of JTE-852, a novel Syk inhibitor, on IgG-mediated cellular responses and autoimmune reactions in vivo. Main methods: We examined mediator secretion from human monocytes. We also conducted rat models of reversed cutaneous anaphylaxis (RCA) and reversed passive Arthus (RPA), which are classified as type II and type III hypersensitivities, respectively. In a rat collagen-induced arthritis (CIA) model, JTE-852 or methotrexate was administered preventively (before the onset of arthritis) or therapeutically (after the onset of arthritis). Key findings: JTE-852 blocked secretion of reactive oxygen species and tumor necrosis factor-α from monocytes stimulated by IgG crosslinking. In the RCA and RPA models, JTE-852 also suppressed edema and dye leakage, respectively. In the CIA model, JTE-852 showed both preventive and therapeutic effects against joint swelling and bone erosion; on the other hand, methotrexate did not show the therapeutic effect. Significance: JTE-852 attenuates IgG-mediated responses and signs in animal model of autoimmune diseases. JTE-852 is thus a promising candidate for a novel, orally available drug for the treatment of autoimmune diseases.
Language	English
Publishing date	2017-12-15
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	3378-9
ISSN	1879-0631 ; 0024-3205
ISSN (online)	1879-0631
ISSN	0024-3205
DOI	10.1016/j.lfs.2017.10.029
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uc I Zs.368: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: JTE-852, a novel spleen tyrosine kinase inhibitor, blocks mediator secretion from mast cells with immunoglobulin E crosslinking.

Kato, Toshinobu / Iwasaki, Hidenori / Kobayashi, Hatsue / Miyagawa, Naoki / Matsuo, Akira / Hata, Takahiro / Matsushita, Mutsuyoshi

European journal of pharmacology

2017 Volume 801, Page(s) 1–8

Abstract: Mast cells stimulated by immunoglobulin E (IgE)-crosslinking secrete mediators, which are mainly categorized into three groups: granule contents, arachidonate metabolites, and cytokines. These mediators play important roles in pathogenesis of allergic ... ...

Abstract	Mast cells stimulated by immunoglobulin E (IgE)-crosslinking secrete mediators, which are mainly categorized into three groups: granule contents, arachidonate metabolites, and cytokines. These mediators play important roles in pathogenesis of allergic diseases; indeed, some conventional drugs which target the mediators are used in clinical practices. However, these drugs are not yet sufficient enough in their efficacy. That is because most of them are blockers of single mediators and are unable to prevent simultaneously various reactions caused by the three group mediators. Spleen tyrosine kinase (Syk) is a non-receptor protein tyrosine kinase. In mast cells, Syk locates at almost top of the signal cascades induced by IgE-crosslinking and plays pivotal roles in secretion of the three groups of mediators. Therefore, inhibition of Syk would suppress the secretion of all the mediators from mast cells and be a promising-treatment strategy for allergic diseases. In the present study, we characterized pharmacological profiles of JTE-852, which was identified as a novel Syk inhibitor. JTE-852 inhibited kinase activity of Syk in an adenosine 5'-triphosphate (ATP)-competitive fashion. JTE-852 also blocked the secretion of granule contents, arachidonate metabolites, and cytokines from mast cells stimulated by IgE-crosslinking, with similar potencies. The results suggest that JTE-852 is supposed to prevent various allergic reactions caused by the three group mediators in vivo. In fact, oral gavage of JTE-852 attenuated an allergic reaction mediated by histamine, which is a representative of the three groups of mediators. JTE-852 is expected to be a novel, highly-efficacious, and orally available anti-allergic drug.
MeSH term(s)	Aminopyridines/pharmacology ; Animals ; Cell Line, Tumor ; Immunoglobulin E/immunology ; Intracellular Space/drug effects ; Intracellular Space/metabolism ; Mast Cells/cytology ; Mast Cells/drug effects ; Mast Cells/immunology ; Mast Cells/metabolism ; Passive Cutaneous Anaphylaxis/drug effects ; Protein Kinase Inhibitors/pharmacology ; Rats ; Rats, Sprague-Dawley ; Syk Kinase/antagonists & inhibitors ; Syk Kinase/metabolism ; Thiazoles/pharmacology
Chemical Substances	Aminopyridines ; JTE-852 ; Protein Kinase Inhibitors ; Thiazoles ; Immunoglobulin E (37341-29-0) ; Syk Kinase (EC 2.7.10.2)
Language	English
Publishing date	2017-04-15
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	80121-5
ISSN	1879-0712 ; 0014-2999
ISSN (online)	1879-0712
ISSN	0014-2999
DOI	10.1016/j.ejphar.2017.02.048
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 522: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito